Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

RSV Infection: early-phase trial registry

3 of 9 indexed RSV Infection trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 3 currently recruiting · #1,916 of 28,707 conditions by registered trial count

RSV Infection: 9 US clinical trials tracked, 3 recruiting.

RSV Infection is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Enanta Pharmaceuticals, running 3 of these trials.

Enrollment posture brief

Registry condition rsv-infection

OPEN 3 | RECR 33% | LATE 2 | EARLY 4 | RANK #1916 | SPON 3

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%RSV Infection (this)33%Acute Otitis Media22.2%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near RSV Infection

RSV Infection lists 3 open slots (33% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for RSV Infection on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. RSV Infection is recruiting below its size-band peers.

    3 of 9 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates RSV Infection research.

    Enanta Pharmaceuticals accounts for 3 of 9 trials (33.3%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Typical RSV Infection enrolment sits around 160 participants.

    Median target enrolment is 160 among the 9 trials that report a genuine target (sentinel values excluded). 4 of those (44.4%) plan for fewer than 100 participants.

  4. RSV Infection splits between interventional and observational designs.

    6 interventional and 3 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 32

Open and recent trials

9 total, page 1 of 1

RECRUITING 3,750 participants

Real-World Effectiveness of Perinatal RSV Immunoprophylaxis

Yale University

NCT06172660

RECRUITING Phase 3 550 participants

A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose

Pfizer

NCT06866405

RECRUITING Phase 1 160 participants

Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults

Clover Biopharmaceuticals USA

NCT06843317

ACTIVE NOT RECRUITING 300 participants

SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies

The Geneva Foundation

NCT05765396

COMPLETED Phase 3 1,003 participants

Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)

Merck Sharp & Dohme

NCT04938830

COMPLETED Phase 1 82 participants

A Study of EDP-323 in Healthy Subjects

Enanta Pharmaceuticals

NCT05587478

COMPLETED 60 participants

Exhaled Nitric Oxide in Respiratory Syncytial Virus (RSV) Bronchiolitis: a Pilot Study

Winthrop University Hospital

NCT01090557

COMPLETED Phase 1 48 participants

A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.

Enanta Pharmaceuticals

NCT06847464

COMPLETED Phase 1 24 participants

A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants

Enanta Pharmaceuticals

NCT06917508

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 3 2

Named interventions

Most-linked intervention names on RSV Infection records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

EDP-323 Drug
3 trials
Placebo Biological
2 trials
Collection of exhaled breath Other
1 trials
Palivizumab Biological
1 trials
Clesrovimab Biological
1 trials
imPulse™ Systems (Una and TOR) infrasound-to-ultrasound e-stethoscope Device
1 trials
Nirsevimab Drug
1 trials
carbamazepine Drug
1 trials

US sites by state

Facility locations filed on RSV Infection trials. A trial with sites in several states counts in each.

Texas 3 trials
New York 2 trials
Kentucky 2 trials
Florida 2 trials
Colorado 2 trials
California 2 trials
Tennessee 1 trials
South Carolina 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this RSV Infection page

9 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This RSV Infection condition card totals 9 registered trials; most-linked intervention EDP-323; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.